CN1205981C - Pharmaceutical composition for colitis - Google Patents
Pharmaceutical composition for colitis Download PDFInfo
- Publication number
- CN1205981C CN1205981C CN 03111836 CN03111836A CN1205981C CN 1205981 C CN1205981 C CN 1205981C CN 03111836 CN03111836 CN 03111836 CN 03111836 A CN03111836 A CN 03111836A CN 1205981 C CN1205981 C CN 1205981C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- parts
- present
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention belongs to a medicinal composition for curing colonitis, particularly to a traditional Chinese medicine medicinal compositioin for curing colonitis. The present invention discloses a medicinal composition for curing colonitis, which is a medicine prepared from the raw materials and the auxiliary materials of the following proportion by weight: 450 to 600 parts of milkvetch root, 150 to 260 parts of dangshen, 80 to 180 parts of dried ginger, 140 to 240 parts of largehead atractylodes rhizome, 140 to 240 parts of white peony alba (saute), 80 to 180 parts of common aucklandia root, 140 to 240 parts of villous amomum fruit, 140 to 240 parts of Chinese magnolivine fruit, 140 to 240 parts of Chinese pulsatilla root and 40 to 80 parts of licorice root. The medicine of the present invention has the advantages of conspicuous curative effect and low cost, and is a medicinal composition of a pure traditional Chinese medicine preparation for curing colitis.
Description
(1) described technical field
The invention belongs to the treatment colitis by pharmaceutical composition, particularly a kind of pharmaceutical composition of treatment by Chinese herbs colitis.
(2) background technology
Chronic non-specific ulcerative colitis is to be comparatively common clinically a kind of digestive tract disease of pathological characteristic with mucous membrane of colon chronic inflammatory disease and ulcer.In recent years document shows that this sick sickness rate has the trend that obviously increases, and has been subjected to the generally attention of medical circle.Primary disease healing difficulty is big, outbreak repeatedly, and in close relations with colon cancer, the precancerous lesion that especially extent of disease is extensive, the course of disease is considered to colon cancer than the elder.Classified as one of modern difficult treatment by World Health Organization (WHO) at present.
(3) summary of the invention
The pharmaceutical composition that the objective of the invention is to the treatment colitis of evident in efficacy, pure Chinese medicinal preparation.
The object of the present invention is achieved like this:
The invention discloses a kind of pharmaceutical composition for the treatment of colitis, is the medicament of being made by following weight proportion raw material and adjuvant:
Radix Astragali 450-600 Radix Codonopsis 150-260 Rhizoma Zingiberis 80-180
Rhizoma Atractylodis Macrocephalae 140-240 Radix Paeoniae Alba (parched) 140-240 Radix Aucklandiae 80-180
Fructus Amomi 140-240 Fructus Schisandrae Chinensis 140-240 Radix Pulsatillae 140-240
Radix Glycyrrhizae 40-80.
Medicine of the present invention, its preferred proportioning raw materials is:
Radix Astragali 500-560 Radix Codonopsis 180-250 Rhizoma Zingiberis 100-150
Rhizoma Atractylodis Macrocephalae 160-220 Radix Paeoniae Alba (parched) 160-220 Radix Aucklandiae 100-150
Fructus Amomi 160-220 Fructus Schisandrae Chinensis 160-220 Radix Pulsatillae 160-220
Radix Glycyrrhizae 50-80.
Pharmaceutical composition of the present invention is preferably made a material agent, pill, tablet.
Below medicine of the present invention is done further to analyze:
1. the function of medicine of the present invention cures mainly
Medicine of the present invention has replenishing QI to invigorate the spleen, bowel relieving intestinal stasis relieving, astringent or styptic treatment for spontaneous sweating antidiarrheal.Be used for chronic non-specific ulcerative colitis (chronic recurrent, chronic lasting type and first hair style, active stage and catabasis), differential diagnosis in tcm belongs to the damp-retention due to hypofunction of the spleen card, and disease is seen: diarrhoea, passing stool with blood and pus or mucus, chronic diarrhea is not healed, lack of appetite abdominal distention, limbs asthenia, spiritlessness and sparing of words, meet the raw food of trembling with fear or take food and increase the weight of pale tongue with white fur, deep-thready pulse etc.
The Radix Astragali is the key medicine of QI invigorating, and " medicine origin " says its " kind control weakness of the spleen and stomach ", and large usage quantity focuses on the deficiency of vital energy of tonifying the spleen and stomach; Radix Codonopsis is arrogated to oneself invigorating middle warmer gas, and " Bencao Congxin " claims its " invigorating the spleen and replenishing QI and taste ", cures mainly syndrome of deficiency of spleen qi and stomach qi with the Radix Astragali, so be principal agent in the side altogether.Rhizoma Zingiberis, the taste of being good at loosing are cold, help the taste yang-energy, be warm in Jiao's principal agent, the Shennong's Herbal cloud: " warding off diarrhea " by intestinal, with Radix Codonopsis with using warming and invigorating the spleen and stomach yang-energy and diffusing Deficiency and coldness of spleen and stomach, with Zhi Qiben; The Rhizoma Atractylodis Macrocephalae is bitter sweet warm in nature, in the sweet temperature compensation, and the kind especially invigorating the spleen and regulating the stomach of dispelling the damp pathogen with bitter and warm drugs, parching with earth; Two medicine compatibilities strengthen the spleen invigorating of monarch drug invigorating middle warmer gas and render a service; The Radix Paeoniae Alba is fried with yin fluid astringing pain relieving power and wins, with Radix Codonopsis 5 invigorating middle warmer gas and end stomachache mutually, with the Rhizoma Atractylodis Macrocephalae 5 enriching spleen-QIs and remove diarrhoea mutually, " book on Chinese herbal medicine performance " say its " Radix Paeoniae Alba medicated wine fry with the Rhizoma Atractylodis Macrocephalae with then spleen reinforcing, use then QI invigorating together with Radix Ginseng "; So above three flavors are ministerial drug altogether.The Radix Aucklandiae, merit is arrogated to oneself the promoting the circulation of QI to relieve pain that are good for the stomach, intestinal stasis relieving in the accent, that uses in the side both treats and lets out dysentery, lends its fragrance a surname logical property again, prevents from that the Qi-tonifying drug temperature compensation from stopping up to stagnate; Fructus Amomi, promoting the circulation of QI to alleviate the stagnation in middle-JIAO, warming spleen and stopping diarrha, " book on Chinese herbal medicine is looked for the truth " cloud its " go into large intestine then in red, to let out dysentery in vain effective ", with the Radix Aucklandiae with then the hot temperature of loosing is logical, conductance humidity hysteresis in the accent; The Radix Pulsatillae, heat-clearing and toxic substances removing dampness removing heat from blood is the key medicine of treatment dysentery pus and blood, with the Radix Aucklandiae, Fructus Amomi 5 bowel relieving intestinal stasis relieving mutually, except that ambassador's pus and blood mucus; Fructus Schisandrae Chinensis sour in the mouth warm in nature is gone into lung, kidney, heart channel, for relieving diarrhea with astringents control that chronic diarrhea do not heal will product, with the Radix Aucklandiae, Fructus Amomi mutually 5, among the bowel relieving intestinal stasis relieving and astringent or styptic treatment for spontaneous sweating antidiarrheal,, promote the healing of intestinal ulcer surface with the Radix Paeoniae Alba 5 astringings to arrest diarrhea mutually; More than four the flavor be adjuvant drug altogether.Radix Glycyrrhizae, invigorating the spleen and replenishing QI, relieving spasm to stop pain, and have and be in harmonious proportion the merit of the property of medicine, with Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the Radix Astragali mutually 5, replenishing QI to invigorate the spleen makes the vigorous spleen being able to resist against invasion of pathogen, and the strong stopping leak dysentery that wets that then can win of temper has the merit of adjuvant drug, and coordinating the actions of various ingredients in a prescription has the energy of messenger drug.
More than all medicine compatibilities, play replenishing QI to invigorate the spleen altogether, bowel relieving intestinal stasis relieving, the merit of astringent or styptic treatment for spontaneous sweating antidiarrheal.Take an overall view of full side, strengthening the spleen and stomach and dry stagnant, antidiarrheal dysentery and hold back the pus infections, astringing intestine to stop diarrhea and end chronic diarrhea, the prescription compatibility, law is tight, for what treat this disease the efficacious prescriptions medicine is arranged.
2. preparation technology
2.1 extraction process design
Extraction process is divided into following three aspects:
Extract the medicine of volatile oil: Rhizoma Zingiberis, the Radix Aucklandiae, Fructus Amomi, the Rhizoma Atractylodis Macrocephalae (stir-fry).
The medicine of water boiling and extraction: the medicinal residues behind the Radix Astragali, Radix Codonopsis, Radix Glycyrrhizae and the extraction volatile oil.
The medicine of alcohol reflux: the Radix Paeoniae Alba, Fructus Schisandrae Chinensis, the Radix Pulsatillae.
2.2 extraction process condition research
1. extract volatile oil: is index with the volatile oil extracted amount with the time of carrying most volatile oil needs, has investigated the two influence to extracting.The result shows, pulverizing medicinal materials is become coarse powder, adds 5 times of water gagings, and steam distillation extracted volatile oil 4 hours, carries to the greatest extent to volatile oil, is optimum condition.
2. water extraction condition: the investigation factor comprises the medical material granularity, solvent load, extraction time and extraction time.According to water boiling and extraction condition orthogonal experiments, determine that medical material decocts with water secondary, add 10 times of water gagings for the first time, decocted 3 hours, add 6 times of water gagings for the second time, decocted 2 hours.
3. ethanol extraction condition: with paeoniflorin, schisandrin B content is index, investigates extraction conditions, and orthogonal test and The results of analysis of variance show, pulverizing medicinal materials becomes coarse powder, add 70% ethanol extraction 2 times, add 8 times of amounts for the first time, add 6 times of each extractions 2 hours of amount for the second time.
2.3 the research of preparations shaping
1. volatile oil beta-ring-type is stuck with paste the research of clear encapsulating method
Seal volatile oil L9 orthogonal test and ANOVA showed significant through β-ring-type spermatophore: get the cycloheptaamylose that volatile oil adds 5 times of amounts, add 2 times of amounts (β-CD amount), 20% ethanol and grind to form and stick with paste new shape, added volatile oil 2 hours, get pastel.Cold drying is optimum condition.
2. the research of moulding process
The ratio of finding sucrose and dextrin during experiment is to preparing particulate difficulty or ease, making graininess and particulate solubility property has bigger influence.For this reason, inquired into both different ratios to making particulate influence, the result shows: Icing Sugar and the ratio of dextrin are to mix at 1: 1 when making auxilliary grain, and granule character, the dissolubility of making are all better.
3. pharmacology pharmacodynamic research
According to medicine of the present invention, function cures mainly, and chooses the positive contrast medicine of enteritis ball.Carry out following 10 16 kinds of pharmacodynamics tests altogether:
3.1 medicine analgesic activity of the present invention
1. the analgesic activity result that medicine Dichlorodiphenyl Acetate of the present invention causes the pain mice shows: what the large, medium and small dosage group of medicine of the present invention can reduce significantly all that acetic acid causes the pain mice turns round the body number of times, with ordinary water group ratio
*P＜0.05 illustrates the capable analgesic activity preferably of medicine of the present invention, but analgesia is had no significant effect incubation period.
2. medicine of the present invention shows the analgesic activity result of hot plate mice: the heavy dose of group of medicine of the present invention all can significantly improve hot plate mice threshold value in 0.5 and 1 hour behind medicine, with the ordinary water group than P＜0.05, with positive group than P＜0.05.
3.2 medicine antiinflammatory action of the present invention
1. medicine of the present invention is to the influence of mice capillary permeability, and the result shows that medicine small dose group of the present invention has significant inhibitory effect to the mice capillary permeability, compares P＜0.05 with the ordinary water group.
2. medicine of the present invention is to the influence of mice auricle swelling, and the result shows, the big or middle dosage group of medicine of the present invention all can highly significant suppresses the mice auricle swelling that caused by dimethylbenzene, with the ordinary water group than P＜0.01; Its big or middle dosage group has antiinflammatory action preferably.
3. medicine of the present invention shows the bullate result of influence of rat granuloma: big or middle dosage group of medicine of the present invention and ordinary water group comparison rat granuloma swell remarkable inhibitory action (P＜0.01, P＜0.05) are all arranged; Heavy dose of group than positive drug group strong (P＜0.05), illustrates that medicine of the present invention also has antiinflammatory action preferably to chronic inflammatory disease to the bullate inhibitory action of rat granuloma.
3.3 medicine of the present invention is to the effect of small intestine movement of mice function
1. medicine of the present invention shows the propulsive result of influence of small intestine movement of mice: heavy dose of group of medicine of the present invention and positive drug group and ordinary water group are than P＜0.01; In dosage group and ordinary water group than P＜0.05, illustrate that the big or middle dosage group of medicine of the present invention advances mice charcoal end remarkable inhibitory action is arranged.
2. medicine of the present invention shows the stopping leak exercising result of normal mouse, compare with the ordinary water group, the large, medium and small dosage group of medicine of the present invention can both significant prolongation mouse gavaging Oleum Ricini dehumidifying excrement incubation period, in, small dose group can both significantly reduce muck rate and muck number, diarrhea due to the mouse gavaging Oleum Ricini there is significant inhibitory effect, suitable with positive drug.
3.4 medicine of the present invention is to the influence of the intestinal function of mice with spleen deficiency
1. medicine of the present invention shows the result that influences of mice with spleen deficiency intestinal propulsion, with the ordinary water group relatively, in the medicine of the present invention, small dose group can both significantly suppress the charcoal end in the enteral propelling of mice with spleen deficiency, and is suitable with positive drug.
2. the result that influences that medicine of the present invention is had loose bowels to mice with spleen deficiency shows, compare with the ordinary water group, in the medicine of the present invention, small dose group can both significantly reduce mice with spleen deficiency and gavage Oleum Ricini muck rate, illustrates that medicine of the present invention has significant inhibitory effect to the diarrhea that mice with spleen deficiency gavages due to the Semen Ricini.
3.5 medicine of the present invention is to the progradation of small intestinal superfunction mouse small intestine
The result shows that the heavy dose of group of medicine of the present invention can significantly suppress the propelling of charcoal end in the hyperfunction mouse small intestine of intestinal, and is suitable with positive drug.
3.6 medicine of the present invention is to the influence of small intestinal absorption function
The result shows, with the ordinary water group relatively, in the medicine of the present invention, small dose group has extremely significant rising effect to the content of D-xylose in the mice serum; Compare with the positive drug group, medicine small dose group of the present invention also has the effect of the D-xylose content in the mice serum that extremely significantly raises.Therefore, medicine of the present invention is absorbed with remarkable facilitation to mouse small intestine.
3.7 medicine of the present invention is to the effect of ulcerative colitis rat model
Presentation of results compares with the ordinary water group, and the large, medium and small dosage group of medicine of the present invention can both significantly increase ulcerative colitis rat model The Total albumen content, compares with positive drug, and remarkable increase effect is also arranged.
3.8 medicine of the present invention is to the refrigeration function of rabbit
The result shows, compares with the ordinary water group, and the large, medium and small dosage group of medicine of the present invention after giving 10% yeast 12h, can significantly reduce the body temperature of rabbit, and is more Zao than positive drug onset.Illustrate that medicine of the present invention to the rabbit fever models due to 10% yeast, has good refrigeration function.
3.9 medicine of the present invention is to the effect of rabbit intestinal smooth muscle
The result shows, and compares before the medication, and the large, medium and small dosage group of medicine of the present invention all has obvious facilitation to the contraction of rabbit myenteron.
3.10 the bacteriostatic experiment of medicine of the present invention
1. the external bacteriostatic experiment of medicine of the present invention
The result shows that medicine of the present invention is 10mg/ml to the Mlc of staphylococcus aureus and dust Xi Shi bacillus; Staphylococcus aureus there is stronger bactericidal action.
2. bacteriostatic experiment in the medicine body of the present invention
The result shows, compares with the ordinary water group, and medicine of the present invention has significant endogenous protective effect to the mice of staphylococcus aureus, coli-infection.
More than test shows: medicine of the present invention has obvious anti-inflammatory and analgesic effect, to the auricular concha swelling of mice dimethylbenzene and rat granuloma are swollen remarkable inhibitory action is arranged, and the mice capillary permeability is had remarkable inhibitory action; Hot plate is caused pain mice and acetic acid to be caused and turns round the body mice remarkable analgesic activity is arranged; Effect with significant relieving diarrhea with astringents has significant inhibitory effect to the intestinal propulsion of the hyperfunction mice of normal mouse and intestinal function, and mice with spleen deficiency and normal mouse are had significant inhibitory effect by cathartic muck rate due to the Oleum Ricini; Can significantly improve the small intestinal absorption function, the mouse small intestine xylose is absorbed with significant enhancement effect; The ulcerative colitis rat model is had significant therapeutic effect, the colonic ulcer of rat model is had significant healing effect, and can significantly improve the total protein content in the rat model serum; The effect of regulating the flow of vital energy is preferably arranged, to tangible diastole effect being arranged at body man rabbit uterus, intestinal smooth muscle; The better antipyretic effect is arranged, fever model rabbit body temperature due to the yeast is had remarkable reduction effect.Antibacterial action is preferably arranged, and the inside and outside bacteriostatic experiment shows that escherichia coli and staphylococcus aureus are all had bacteriostasis preferably.Above result is the basis of its performance clinical efficacy.
4. toxicological test
4.1 medicine animal acute toxicity test research of the present invention
The mice maximum dosage-feeding is 240g/kg, is 300 times of the clinical consumption of people.Observed 7 days behind the mouse stomach, do not see death and other abnormal phenomenas, body weight gain is normal, and appetite is good.Put to death after 7 days, the ANOMALOUS VARIATIONS of internal organs is not seen in perusal yet, and the overt toxicity reaction does not appear in mice, and it is safe pointing out clinical use.
4.2 medicine rat long term toxicity test research of the present invention
This experimental observation the long term toxicity of three months (12 week) of medicine continuous irrigation stomach of the present invention to rat.Get 160 of healthy Wistar rats, male and female half and half, be divided into four groups of (dosage group, medicine small dose group of the present invention in matched group, the heavy dose of group of medicine of the present invention, the medicine of the present invention) every morning gastric infusions at random by body weight, administration is 7 days weekly, 12 weeks of successive administration, situations such as outward appearance of perusal every day animal and general behavior and appetite, defecation.Regularly weigh in, carry out hematology and blood biochemical and learn inspection.And 60 days, 90 days, 120 days (convalescent period) of open medicine animal is cutd open inspection, taking internal organ is weighed and is carried out histopathological examination.Result of the test shows, rat successive administration 90 days, every indexs such as each administration group rats eating, movable normal, body weight all have growth in various degree before than administration, and the hematology detects, blood biochemical is learned detections and organ coefficient and matched group compare no significant difference (P＞0.05).Internal organs such as each administration treated animal heart of histopathologic examination, liver, spleen, lung, kidney, stomach, thymus, adrenal gland, uterus, ovary, testis, prostate and matched group relatively there is no obvious pathomorphology and change.
Therefore, that medicine of the present invention has is evident in efficacy, cost is lower, is the pharmaceutical composition of the treatment colitis of pure Chinese medicinal preparation.
(4) specific embodiment
1. embodiment 1
Prescription:
Radix Astragali 450g Radix Codonopsis 150g Rhizoma Zingiberis 180g
Rhizoma Atractylodis Macrocephalae 140g Radix Paeoniae Alba (parched) 140g Radix Aucklandiae 180g
The Fructus Amomi 240g 240g Radix Pulsatillae 140g that distinguishes the flavor of
Radix Glycyrrhizae 80g
Method for making: above ten flavors, get the Rhizoma Atractylodis Macrocephalae (stir-frys), the Radix Aucklandiae, Rhizoma Zingiberis, amomum powder and be broken into coarse powder, extract volatile oil, the device collection in addition of the aqueous solution after the distillation; The medicinal residues and the Radix Astragali, Radix Codonopsis, Radix Glycyrrhizae decoct with water secondary, and 3 hours for the first time, 2 hours for the second time, merge decoction liquor, filter, filtrate and above-mentioned aqueous solution merge, and being condensed into relative density is the clear paste of 1.30～1.32 (55 ℃).Radix Paeoniae Alba (parched), Fructus Schisandrae Chinensis, the Radix Pulsatillae are ground into coarse powder, add 70% alcohol heating reflux and extract secondary, each 2 hours, merge extractive liquid,, filter, filtrate recycling ethanol, being condensed into relative density is the clear paste of 1.30～1.32 (55 ℃), merge with above-mentioned clear paste, drying under reduced pressure is ground into dry extract.Get 5 times of volatile quantity cycloheptaamyloses, add 2 times of amount 20% ethanol, grind to form pasty state, add above-mentioned volatile oil, ground 2 hours, cold drying is ground into fine powder, with above-mentioned dry extract mixing, add an amount of cane sugar powder and dextrin mixture (1: 1) and ethanol, system granule, cold drying, make granule 1000g, promptly.
By every bag of 8g, make finished product, boiled water is taken after mixing it with water, one time one bag, 3 times on the one.
2. embodiment 2
Radix Astragali 600g Radix Codonopsis 260g Rhizoma Zingiberis 80g
Rhizoma Atractylodis Macrocephalae 240g Radix Paeoniae Alba (parched) 240g Radix Aucklandiae 80g
Fructus Amomi 140g Fructus Schisandrae Chinensis 140g Radix Pulsatillae 240g
Radix Glycyrrhizae 40g
With above-mentioned raw material, identical with the method for making of embodiment 1, merge paste and make clear paste.Get 5 times of volatile quantity cycloheptaamyloses again, add 2 times of amount 20% ethanol, grind to form pasty state, add volatile oil, ground 2 hours, the clear paste ground and mixed with above-mentioned makes pill, every ball 8g.Boiled water is taken after mixing it with water, one time one ball, three times on the one.
3. embodiment 3
Radix Astragali 500g Radix Codonopsis 250g Rhizoma Zingiberis 150g
Rhizoma Atractylodis Macrocephalae 160g Radix Paeoniae Alba (parched) 220g Radix Aucklandiae 100g
Fructus Amomi 220g Fructus Schisandrae Chinensis 220g Radix Pulsatillae 220g
Radix Glycyrrhizae 50g
Method for making is identical with embodiment 1.
4. embodiment 4
Radix Astragali 560g Radix Codonopsis 180g Rhizoma Zingiberis 100g
Rhizoma Atractylodis Macrocephalae 220g Radix Paeoniae Alba (parched) 160g Radix Aucklandiae 150g
Fructus Amomi 160g Fructus Schisandrae Chinensis 160g Radix Pulsatillae 160g
Radix Glycyrrhizae 70g
With above-mentioned raw material, identical with the method for making of embodiment 1, merge clear paste, add a spot of amylum pregelatinisatum, tabletting, every 4g.Boiled water is taken after mixing it with water, one time 2, three times on the one.
5. embodiment 5
Radix Astragali 510g Radix Codonopsis 200g Rhizoma Zingiberis 120g
Rhizoma Atractylodis Macrocephalae 180g Radix Paeoniae Alba (parched) 180g Radix Aucklandiae 130g
The Fructus Amomi 180g Fructus Schisandrae Chinensis 180g Radix Pulsatillae 200
Radix Glycyrrhizae 60g
With above-mentioned raw material, identical with the method for making of embodiment 1, merge clear paste, add a spot of starch, make capsule, each capsule powder charge 2g.Boiled water is taken after mixing it with water, one time 4, three times on the one.
Claims (3)
1. a pharmaceutical composition for the treatment of colitis is characterized in that: be the medicament of being made by following weight proportion raw material and other adjuvant
Radix Astragali 450-600 Radix Codonopsis 150-260 Rhizoma Zingiberis 80-180
Rhizoma Atractylodis Macrocephalae 140-240 Radix Paeoniae Alba (parched) 140-240 Radix Aucklandiae 80-180
Fructus Amomi 140-240 Fructus Schisandrae Chinensis 140-240 Radix Pulsatillae 140-240
Radix Glycyrrhizae 40-80.
2. the pharmaceutical composition of treatment colitis according to claim 1 is characterized in that: wherein the weight proportion of each raw material is
Radix Astragali 500-560 Radix Codonopsis 180-250 Rhizoma Zingiberis 100-150
Rhizoma Atractylodis Macrocephalae 160-220 Radix Paeoniae Alba (parched) 160-220 Radix Aucklandiae 100-150
The Fructus Amomi 160-220 160-220 Radix Pulsatillae 160-220 that distinguishes the flavor of
Radix Glycyrrhizae 50-80.
3. the pharmaceutical composition of treatment colitis according to claim 1 is characterized in that: make a material agent, pill, tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03111836 CN1205981C (en) | 2003-01-28 | 2003-01-28 | Pharmaceutical composition for colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03111836 CN1205981C (en) | 2003-01-28 | 2003-01-28 | Pharmaceutical composition for colitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1520860A CN1520860A (en) | 2004-08-18 |
| CN1205981C true CN1205981C (en) | 2005-06-15 |
Family
ID=34283526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03111836 Expired - Fee Related CN1205981C (en) | 2003-01-28 | 2003-01-28 | Pharmaceutical composition for colitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1205981C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106492151A (en) * | 2016-11-01 | 2017-03-15 | 张志明 | A kind of Chinese medicine composition for treating colitis |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299761C (en) * | 2005-04-29 | 2007-02-14 | 王政平 | Medicinal composition for treating colonitis and its preparation method |
| CN102861305B (en) * | 2012-09-10 | 2015-01-07 | 侯保明 | Medicament for treating acute and chronic colonitis |
| CN103263630B (en) * | 2013-05-30 | 2014-09-03 | 李伟丽 | Pharmaceutical composition for promoting healing of anastomotic stoma after colonic anastomosis surgery |
| CN104825965A (en) * | 2015-04-24 | 2015-08-12 | 李万青 | Chinese medicinal composition for treatment of gastroenteritis |
| CN104825442B (en) * | 2015-04-30 | 2018-02-23 | 浙江鼎辉医药科技有限公司 | Application of the deoxyschizandrin in prevention colitis or colon cancer drug is prepared |
| CN111759978B (en) * | 2020-07-06 | 2021-10-22 | 河北省中医院 | Traditional Chinese medicine composition for treating ulcerative colitis and eczema as well as preparation method and application thereof |
-
2003
- 2003-01-28 CN CN 03111836 patent/CN1205981C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106492151A (en) * | 2016-11-01 | 2017-03-15 | 张志明 | A kind of Chinese medicine composition for treating colitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1520860A (en) | 2004-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066445A (en) | Chinese medicine prepn for curing gastropathy radically | |
| CN103099959B (en) | Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof | |
| CN105343625A (en) | Taraxacum oral liquid for expelling toxin, dehumidifying and benefiting gallbladder and preparation method thereof | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN101972338A (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
| CN104173969A (en) | Traditional Chinese medicine preparation for treating chronic gastritis caused by deficient cold of spleen and stomach and preparation method thereof | |
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN1205981C (en) | Pharmaceutical composition for colitis | |
| CN1278718C (en) | Traditional Chinese medicine compound preparation for preventing and treating intestinal adhesion and preparing method | |
| CN103330914B (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN104162129A (en) | Traditional Chinese medicine for treating diabetic gastroparesis | |
| CN1243561C (en) | Chinese medicine for cancer | |
| CN103599343B (en) | A kind of pharmaceutical composition for the treatment of diabetes and its production and use | |
| CN104001131A (en) | Oral traditional Chinese medicine for preventing and treating stress ulcers | |
| CN101327293B (en) | Capsules for treating peptic ulcer and preparation method thereof | |
| CN106110169A (en) | The Chinese medicine composition for the treatment of flatulence pain | |
| CN105214037A (en) | The solid dispersal capsule for the treatment of peptic ulcer | |
| CN104873911A (en) | Traditional Chinese medicine for oral administration for adjunctively treating sepsis | |
| CN104435641A (en) | Traditional Chinese medicine preparation for treating hyperthyroidism | |
| CN104758676A (en) | Medicine for treating damp-heat in resistance-type epigastric pain | |
| CN100361705C (en) | Chinese medicinal composition for treating chronic atrophic gastritis | |
| CN104083548A (en) | Traditional Chinese medicinal composition for treating ovarian cyst and preparation method thereof | |
| CN103893566A (en) | Giant salamander Chinese herbal medicine compound preparation for treating hepatitis B | |
| CN106668390B (en) | Traditional Chinese medicine composition for treating hyperthyroidism in early and middle stages | |
| CN103028028B (en) | Traditional Chinese medicine agent for treating primary hepatic carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |